Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TT 816

Next Previous
Drug Profile

TT 816

Alternative Names: TT-816

Latest Information Update: 19 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teon Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 31 May 2024 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 07 Sep 2023 Teon Therapeutics terminates a Phase-I/II clinical trials in Solid tumours (Late-stage disease, Monotherapy, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA due to safety and efficacy concern (PO) (NCT05525455)
  • 20 Jan 2023 Teon Therapeutics enters into a clinical trial collaboration with Merck for phase I/II trial of TT 816 and pembrolizumab

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top